CARLSBAD, Calif., Nov. 12, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), announced today the upcoming presentations of clinical and non-clinical data for several of its ...

For decades, antisense technology promised to transform the pharmaceutical industry. That moment has now arrived. Dr. Stanley Crooke, a pioneer in the field, explains what’s next. This article was ...

Diffuse intrinsic pontine glioma (DIPG) is a lethal pediatric brain cancer that often kills within a year of diagnosis. DIPG occurs in an area of the brainstem called the pons, which controls many of ...

People around the globe suffer from a myriad of rare diseases, many of which have no cure or limited treatment options. Many patients have been living without hope of a significant improvement in ...

The voracious growth of all cancers is powered by an alteration in cellular energy consumption. One characteristic of this is the production of a different version of the pyruvate kinase M gene, PK-M2 ...

CARLSBAD, Calif., Oct. 22, 2020 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that the first patients have been dosed with ION541 ...

Over the past decade, antisense technology has weathered many of the trials and tribulations facing any new branch of pharmacology, but it is now coming of age. One antisense drug, Isis ...

Regensburg, Germany, November 2, 2010 / b3c newswire / - The biopharmaceutical company Antisense Pharma announced today that their international, randomized and active-controlled Phase IIb study ...

After a two-decade cycle of investor embrace and rejection, partnerships won and lost, failed clinical trials, layoffs, and rebuilds, Isis Pharmaceuticals has gained approval for the first ...

With so many companies working on multiple approaches to interrupting messenger RNA and, hence, protein production, it comes as no surprise that the intellectual property (IP) surrounding antisense is ...

In November, Isis Pharmaceuticals (Carlsbad, CA) announced the departure of its longstanding partner, Novartis Pharmaceuticals (Basel, Switzerland), leaving the small biotech company to underwrite ...

Effective July, 2011, Antisense Pharma's founder and CEO, Dr. Karl-Hermann Schlingensiepen, will now be a member of the supervisory board and will focus on the company's strategy as a consultant.